Cyclosporin A enhanced protection of nimodipine against brain damage induced by hypoxia-ischemia in mice and rats

Acta Pharmacol Sin. 2002 Mar;23(3):225-9.

Abstract

Aim: To study whether P-glycoprotein (P-gp) inhibitor cyclosporin A (CsA) enhanced the protection of nimodipine (NMD) against brain damage.

Method: (1) After mice were given ip NMD alone or co-administration of CsA, survival time of mice were recorded following decapitation and ip injection of NaNO2, respectively. (2) After rats were given ip NMD alone or co-administration of CsA, 20 min forebrain ischemia induced by the technique of two-carotid occlusion plus hypovolemic hypotension. Following reperfusion of 1 h, the content of malondialdehyde (MDA), lactic acid (LA) and activity of lactic dehydrogenase (LDH) in cortex tissue were measured. (3) NMD level in brain was also determined after ip injection of NMD 2 mg/kg alone and co-administration of CsA, respectively.

Results: NMD showed potent pharmacological activity in the three models. The survival time of mice by decapitation and ip NaNO2 were significantly (P <0.05) prolonged after co-administration of CsA. In rat forebrain ischemia/reperfusion, levels of MDA, LA, and LDH by co-administration of CsA were greatly modified, compared with those of NMD alone group. The level of NMD in rat brain was increased markedly after co-administration of CsA.

Conclusion: P-gp inhibitor CsA may enhance the protection of NMD against brain damage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / antagonists & inhibitors
  • Animals
  • Brain Ischemia / metabolism*
  • Brain Ischemia / prevention & control
  • Calcium Channel Blockers / pharmacology
  • Cerebral Cortex / metabolism
  • Cyclosporine / pharmacology*
  • L-Lactate Dehydrogenase / metabolism
  • Male
  • Malondialdehyde / metabolism
  • Mice
  • Mice, Inbred ICR
  • Neuroprotective Agents / pharmacology*
  • Neuroprotective Agents / therapeutic use
  • Nimodipine / pharmacology*
  • Nimodipine / therapeutic use
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Reperfusion Injury / prevention & control*

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Calcium Channel Blockers
  • Neuroprotective Agents
  • Malondialdehyde
  • Nimodipine
  • Cyclosporine
  • L-Lactate Dehydrogenase